Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11100770 | 0.82 | CA12 (0.58) | KMT2AMEN1GAAALDH1A1PKM | |
| SCHEMBL26648667 | 0.78 | MEN1 (0.53) | KMT2AMEN1CYP1A2CYP3A4GAA | |
| SCHEMBL29530999 | 0.78 | KMT2A (0.53) | KMT2AMEN1CYP1A2CYP3A4GAA | |
| SCHEMBL25320410 | 0.78 | KMT2A (0.53) | KMT2AMEN1CYP1A2CYP3A4GAA | |
| SCHEMBL25684114 | 0.78 | MEN1 (0.57) | KMT2AMEN1CYP1A2CYP3A4GAA | |
| SCHEMBL31255159 | 0.75 | GRM5 (0.46) | KMT2AMEN1GRM5CHRM5CA12 | |
| SCHEMBL16241455 | 0.74 | NR1H2 (0.50) | KMT2AMEN1CYP3A4GAATSHR | |
| SCHEMBL18668991 | 0.74 | MEN1 (0.50) | KMT2AMEN1GAAGRM5CHRM5 | |
| SCHEMBL14329239 | 0.72 | RXFP1 (0.57) | KMT2AMEN1TSHRALDH1A1PKM | |
| SCHEMBL14329317 | 0.71 | RXFP1 (0.44) | KMT2AMEN1TSHRALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441704-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| CN-114728170-B | Compounds active on nuclear receptors | 纽韦卢森公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| EP-4076661-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2022-10-26 | — | — | EP | disclosed |
| CN-114728170-A | Compounds active on nuclear receptors | 纽韦卢森公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210188807-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | ALMIRALL, S.A. (ES) | 2021-06-24 | — | — | US | disclosed |
| US-20210188807-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | ALMIRALL, S.A. (ES) | 2021-06-24 | — | — | US | disclosed |
| WO-2021124279-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021124279-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685727-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | KMT2A 3180/4885MEN1 4625/4885CYP1A2 816/4885 |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | KMT2A 3180/4885MEN1 4625/4885CYP1A2 816/4885 |
| US-12441704-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | KMT2A 3180/4885MEN1 4625/4885CYP1A2 816/4885 |
| US-20210188807-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | KMT2A 3180/4885MEN1 4625/4885CYP1A2 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.